source
- Novo Nordisk's late-stage anti-inflammatory heart drug fails Phase 3 trialNovo Nordisk announced that its experimental anti-inflammatory compound designed to target cardiovascular inflammation did not meet its primary endpoint in a Phase 3 trial. The study was intended…
- AbbVie says Skyrizi maintains strong sales momentum as competition risesAbbVie highlighted that its immunology drug Skyrizi continues to generate robust sales despite increasing competition in the market. The company noted that demand for the therapy remains solid and…